feed,title,long_url,short_url
Benzinga,Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy,https://benzinga.com/analyst-ratings/analyst-color/23/11/35809119/catalents-q1-performance-beat-expectations-analyst-says-main-focus-on-manufacturing,https://da.gd/kqUyGw
